Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating ...

a drug that aims to treat ulcerative colitis and metabolic dysfunction-associated steatohepatitis (MASH). In an unrelated announcement, Lilly said it has cut the price for 2.5-milligram and 5-mg ...

The acquisition highlights FXR314’s commercial potential in MASH patients with combination therapy. Lilly could use FXR314 possibly with its anti-diabetic and obesity drug, tirzepatide.

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

Eli Lilly (NYSE: LLY) stock defied today's market ... colitis and metabolic dysfunction-associated steatohepatitis (MASH). Where to invest $1,000 right now? Our analyst team just revealed what ...